Restriction of tumoricidal gene therapy to selected hepatocellular carcinoma cells

✍ Scribed by S Gagandeep; S Gupta

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 170 KB
• Volume: 24
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.510240554

✦ Synopsis

gene therapy can be developed. These include: 1) improve-

We have investigated whether adenovirally mediated ment of vector efficiency and 2) development of effective delivgene transfer of the thymidine kinase gene to human ery techniques, either of transduced cells or vectors directly hepatocellular carcinoma (HCC) cell lines can sensitize to the liver. It appears that significant in vitro and in vivo these cells to the prodrug ganciclovir and thereby prosmall and large animal experimental work must be pervide a therapeutic option for this intractable cancer. formed before an optimal therapeutic approach can be devel-Two replication-deficient adenoviruses encoding for the oped that will have a realistic chance of success in the clinical herpes simplex virus type-1 (HSV) thymidine kinase setting.

(TK) gene were generated in which expression of TK is under the control of either the human cytomegalovirus ACHILLES A. DEMETRIOU, M.D., Ph.D.

immediate early promoter (CMV) or the human alpha-Cedars-Sinai Medical Center fetoprotein (AFP) promoter/enhancer. We demonstrate Los Angeles, CA that the combination of adenovirally mediated TK gene transfer and ganciclovir treatment effectively inhibits REFERENCES